June 2024, ASCO Annual Meeting, Chicago – The Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform. This study rigorously tested Massive Bio’s existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic data, focused on a multi-study oncology platform.